Email this article Clinical case of a young patient with generalized sarcoidosis and heart disease
- Authors: Muradyants A.A.1,2, Aksenova A.V.1, Pravdyuk N.G.1, Klimenko A.A.1, Chernyaeva A.Y.1, Akhadova A.S.2, Zargaryan-Smurova V.A.1
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
- Federal Center of Brain Research and Neurotechnologies, Federal Medical and Biological Agency
- Issue: Vol 19, No 4 (2025)
- Pages: 75-86
- Section: CASE REPORT
- Published: 17.03.2026
- URL: https://klinitsist.abvpress.ru/Klin/article/view/691
- DOI: https://doi.org/10.17650/1818-8338-2025-19-4-K758
- ID: 691
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
Aim. To demonstrate a multidisciplinary approach in management of a patient with generalized sarcoidosis, heart disease and a life-threatening complication in the form of cerebral infarction which required selection of treatment tactics.
Material and methods. Patient A., 41, presented with sarcoidosis and Löfgren’s syndrome onset at the age of 23 and developed clinically manifested cardiac disease over the next three years. Cardiac sarcoidosis was characterized by complex life-threatening arrhythmias, progression of chronic heart failure, and infarction-like changes in electrocardiograms and echocardiograms necessitating differential diagnosis.
Results. Uncontrolled intermittent use of prednisolone, lack of regular standard therapy for sarcoidosis, and lack of antiarrhythmic therapy largely predetermined the unfavorable course of events, including development of an ischemic stroke at a young age. The development of the cerebral infarction was due to a combination of factors: arrhythmia, newly diagnosed congenital heart defect (patent foramen ovale), hyperhomocysteinemia, and the presence of polymorphisms in the folate cycle genes (MTHFR, MTR).
Conclusion. The diversity of clinical manifestations often leads to diagnostic difficulties and errors. In the absence of adequate therapy, the disease progresses and has an unfavorable prognosis. This article presents a clinical observation of a young patient with generalized sarcoidosis with progressive heart disease, hereditary thrombophilia, patent foramen ovale complicated by the development of a stroke.
About the authors
Anaida A. Muradyants
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center of Brain Research and Neurotechnologies, Federal Medical and Biological Agency
Author for correspondence.
Email: elitarsoft@list.ru
ORCID iD: 0000-0002-5713-2253
Russian Federation, 1 Ostrovityanova St., Moscow 117513; Build. 10, 1 Ostrovityanova St., Moscow 117513
A. V. Aksenova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: elitarsoft@list.ru
ORCID iD: 0000-0002-4259-3807
Russian Federation, 1 Ostrovityanova St., Moscow 117513
N. G. Pravdyuk
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: elitarsoft@list.ru
ORCID iD: 0000-0002-9710-699X
Russian Federation, 1 Ostrovityanova St., Moscow 117513
Alesya A. Klimenko
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: elitarsoft@list.ru
ORCID iD: 0000-0002-7410-9784
MD, PhD, Associate Professor, Head of the Department of Acad. A.I. Nesterov of Faculty Therapy
Russian Federation, 1 Ostrovityanova St., Moscow 117513A. Yu. Chernyaeva
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: elitarsoft@list.ru
ORCID iD: 0000-0002-7142-2484
Russian Federation, 1 Ostrovityanova St., Moscow 117513
A. Sh. Akhadova
Federal Center of Brain Research and Neurotechnologies, Federal Medical and Biological Agency
Email: elitarsoft@list.ru
ORCID iD: 0009-0001-1271-5551
Russian Federation, Build. 10, 1 Ostrovityanova St., Moscow 117513
V. A. Zargaryan-Smurova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: elitarsoft@list.ru
ORCID iD: 0009-0008-8460-4966
Russian Federation, 1 Ostrovityanova St., Moscow 117513
References
- Cheng R.K., Kittleson M.M., Beavers C.J. et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. Diagnosis and management of cardiac sarcoidosis: a scientific statement from the American Heart Association. Circulation 2024;149(21):e1197–216. doi: 10.1161/CIR.0000000000001240
- Reznik E.V., Nguyen T.L., Ustyuzhanin D.V. et al. “Red flags” to diagnose infiltrative cardiomyopathies. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology 2023; 28(1S):5259. (In Russ.). doi: 10.15829/1560-4071-2023-5259
- Giblin G.T., Murphy L., Stewart G.C. et al. Cardiac sarcoidosis: when and how to treat inflammation. Card Fail Rev 2021;7:e17. doi: 10.15420/cfr.2021.16
- Birnie D.H., Kandolin R., Nery P.B. et al. Cardiac manifestations of sarcoidosis: diagnosis and management. Eur Heart J 2017;38(35):2663–70. doi: 10.1093/eurheartj/ehw328
- Iwai K., Sekiguti M., Hosoda Y. et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994;11(1):26–31. PMID: 8036339.
- Savushkina N., Egorova O., Glukhova S. et al. Lefgren’s syndrome: assessment of outcomes. Vrach = The Doctor 2016;(10):46–9. (In Russ.).
- Visser H., Vos K., Zanelli E. et al. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis 2002;61(6):499–504. doi: 10.1136/ard.61.6.499
- Mañá J., Marcoval J., Graells J. et al. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol 1997;133(7):882–8. doi: 10.1001/archderm.1997.03890430098013
- Kirdakov D.F., Fomin V.V., Potekaev N.N. Skin sarcoidosis: clinical variants and prognostic significance. Farmateka 2011;18(231):28–33. (In Russ.).
- Vereckei A., Besenyi Z., Nagy V. et al. Cardiac sarcoidosis: a comprehensive clinical review. Rev Cardiovasc Med 2024;25(2):37. doi: 10.31083/j.rcm2502037
- Houston B.A., Mukherjee M. Cardiac sarcoidosis: clinical manifestations, imaging characteristics, and therapeutic approach. Clin Med Insights Cardiol 2014;8(Suppl 1):31–7. doi: 10.4137/CMC.S15713
- Ringkowski S., Thomas P.S., Herbert C. Interleukin-12 family cytokines and sarcoidosis. Front Pharmacol 2014;5:233. doi: 10.3389/fphar.2014.00233
- Jin R., Yang G., Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 2010;87(5):779–89. doi: 10.1189/jlb.1109766
- Nagai S., Yokomatsu T., Tanizawa K. et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med 2014;53(5):427–33. doi: 10.2169/internalmedicine.53.0794
Supplementary files
